name: Doppler ultrasound of right popliteal vessel


name: Doppler ultrasound of left popliteal vessel


name: Doppler ultrasound of popliteal vessels, bilateral


name: genome-wide microarray analysis of single-nucleotide polymorphism variants, F2 and F5 genes, Leiden variant, in saliva, for risk of venous thromboembolism


name: CT arthrogram of ankle without and with contrast


name: NGS of 77 genes, pan-solid tumor ctDNA in plasma, for 8 fusions, microsatellite instability, mutation burden, single-nucleotide variants, copy number alterations


name: CT arthrogram of elbow without and with contrast


name: barbotage of right shoulder using ultrasound guidance


name: barbotage of left shoulder using ultrasound guidance


name: CT arthrogram of hip without and with contrast


name: CT arthrogram of knee without and with contrast


name: CT arthrogram of wrist without and with contrast


name: birth plan, placenta requested after delivery


name: NAA with probe detection for Human coronavirus HKU1 RNA in nasopharynx


name: genome sequence analysis panel for hereditary breast cancer syndromes, 5+ genes, for sequence and copy number variants


name: NAA with probe detection for Human coronavirus RNA in bronchial specimen


name: NAA with probe detection for Human coronavirus RNA in bronchoalveolar lavage


name: NAA with probe detection for Human coronavirus 229E + HKU1 + NL63 + OC43 RNA


name: NAA with probe detection for Human coronavirus 229E + HKU1 + NL63 + OC43 RNA in aspirate


name: NAA with probe detection for Human coronavirus 229E + HKU1 + NL63 + OC43 RNA in bronchoalveolar lavage


name: NAA with probe detection for Human coronavirus 229E + HKU1 + NL63 + OC43 RNA in sputum


name: NAA with probe detection for Human coronavirus NL63 RNA in bronchial specimen


name: NAA with probe detection for Human coronavirus NL63 RNA in bronchoalveolar lavage


name: NAA with probe detection for Human coronavirus NL63 RNA in nasopharynx


name: NAA with probe detection for Human coronavirus OC43 RNA in bronchial specimen


name: NAA with probe detection for Human coronavirus OC43 RNA in bronchoalveolar lavage


name: NAA with probe detection for Human coronavirus OC43 RNA in nasopharynx


name: NAA with probe detection for Enterovirus RNA in bronchial specimen


name: NAA with probe detection for Escherichia coli DNA in positive blood culture


name: NAA with probe detection for Klebsiella spp DNA


name: NAA with probe detection for Klebsiella spp DNA in positive blood culture


name: NAA with probe detection for adenovirus DNA in bronchial specimen


name: NAA with probe detection for adenovirus DNA in pericardial fluid


name: NAA with probe detection for adenovirus DNA in sputum


name: NAA with probe detection for adenovirus DNA in urethra


name: NAA with probe detection for Enterovirus RNA in bronchoalveolar lavage


name: NAA with probe detection for Enterovirus RNA in skin


name: NAA with probe detection for Enterovirus RNA in sputum


name: NAA with probe detection for Listeria sp DNA


name: NAA with probe detection for Cytomegalovirus DNA in genital specimen


name: NAA with probe detection for Cytomegalovirus DNA in pericardial fluid


name: NAA with probe detection for Epstein Barr virus DNA in pericardial fluid


name: NAA with probe detection for herpes virus 6 DNA in pericardial fluid


name: NAA with probe detection for herpes virus 6 DNA in skin


name: NAA with probe detection for parvovirus B19 DNA in pericardial fluid


name: NAA with probe detection for Proteus sp DNA in positive blood culture


name: NAA with probe detection for Enterobacter spp DNA in positive blood culture


name: NAA with probe detection for Salmonella DNA in positive blood culture


name: NAA with probe detection for Serratia spp DNA


name: NAA with probe detection for Serratia spp DNA in positive blood culture


name: NAA with probe detection for Pseudomonas aeruginosa DNA in positive blood culture


name: NAA with probe detection for Bacteroides fragilis DNA in positive blood culture


name: NAA with probe detection for Neisseria meningitidis DNA in positive blood culture


name: NAA with probe detection for Haemophilus influenzae DNA in positive blood culture


name: peripheral IV line in right side of scalp


name: peripheral IV line in right frontal scalp


name: peripheral IV line in right superficial temporal scalp


name: peripheral IV line in right posterior auricular region of scalp


name: peripheral IV line in left side of scalp


name: peripheral IV line in left frontal scalp


name: peripheral IV line in left superficial temporal scalp


name: peripheral IV line in left posterior auricular region of scalp


name: genome sequence analysis panel for hereditary colon cancer-related disorders, 5+ genes, for sequence and copy number variants


name: genome sequence analysis panel for hereditary neuroendocrine tumor-related disorders, 5+ genes, for sequence and copy number variants


name: therapy for language/speech/voice/communication/auditory processing, individual


name: therapy for language/speech/voice/communication/auditory processing, group


name: bypass thoracic duct to lymphatic vessel


name: bypass cisterna chyli to lymphatic vessel


name: lumbar arthrodesis using facet joint fusion device


name: lumbar arthrodesis, 2 or more joints using facet joint fusion device


name: revision of drainage device of nasal bone


name: revision of internal fixation device of nasal bone


name: revision of external fixation device of nasal bone


name: revision of autologous tissue substitute of nasal bone


name: revision of synthetic substitute of nasal bone


name: revision of nonautologous tissue substitute of nasal bone


name: revision of bone growth stimulator of nasal bone


name: revision of drainage device of facial bone


name: revision of internal fixation device of facial bone


name: revision of external fixation device of facial bone


name: revision of autologous tissue substitute of facial bone


name: revision of synthetic substitute of facial bone


name: revision of nonautologous tissue substitute of facial bone


name: revision of bone growth stimulator of facial bone


name: parental concerns about ability to support child's grief


name: death of parent or parental figure in childhood


name: CT scan of brain showed infratentorial hemorrhage


name: CT scan of brain showed supratentorial hemorrhage


name: computerized ophthalmic diagnostic imaging, anterior segment, with interpretation and report


name: fusion of thoracolumbar vertebral joint using facet joint fusion device


name: insertion of device into thoracic vertebral joints, 2 to 7


name: insertion of spinal stabilization device into thoracic vertebral joints, 2 to 7


name: insertion of device into thoracic vertebral joints, 8 or more


name: insertion of spinal stabilization device into thoracic vertebral joints, 8 or more


name: insertion of spinal stabilization device into thoracolumbar vertebral joint


name: restriction of ductus arteriosus with device


name: insertion of posterior spinal motion preservation device into lumbar vertebral joint


name: insertion of pedicle based carbon/PEEK spinal stabilization device into lumbar vertebral joint


name: insertion of device into 2 or more lumbar vertebral joints


name: insertion of posterior spinal motion preservation device into lumbosacral vertebral joint


name: insertion of pedicle based carbon/PEEK spinal stabilization device into lumbosacral vertebral joint


name: transfer from hospital emergency department


name: transfer from intermediate care facility for individuals with intellectual disability


name: hospice care provided in assisted living facility


name: genetic sequencing for full mutation analysis of PPOX gene in blood or tissue


name: Schistosoma circulating anodic antigen in serum


name: Schistosoma circulating anodic antigen in serum by upconverting particle-lateral flow test


name: Schistosoma circulating anodic antigen in serum by magnetic beads antigen-capture enzyme-linked immunoassay


name: TUBA4A variant of uncertain significance


name: ANXA11 variant of uncertain significance


name: SPTLC1 variant of uncertain significance


name: introduction of antineoplastic into peripheral vein


name: introduction of durvalumab antineoplastic into peripheral vein, percutaneous approach


name: introduction of mosunetuzumab antineoplastic into peripheral vein, percutaneous approach


name: introduction of odronextamab antineoplastic into peripheral vein, percutaneous approach


name: introduction of zanidatamab antineoplastic into peripheral vein, percutaneous approach


name: introduction of atezolizumab antineoplastic into peripheral vein, percutaneous approach


name: introduction of glofitamab antineoplastic into peripheral vein, percutaneous approach


name: introduction of tagraxofusp-erzs antineoplastic into peripheral vein, percutaneous approach


name: introduction of iobenguane I-131 antineoplastic into peripheral vein, percutaneous approach


name: introduction of cytarabine and daunorubicin liposome antineoplastic into peripheral vein, percutaneous approach


name: introduction of treosulfan into peripheral vein, percutaneous approach


name: introduction of lurbinectedin into peripheral vein, percutaneous approach


name: introduction of ciltacabtagene autoleucel into peripheral vein, percutaneous approach


name: introduction of anti-infective into peripheral vein


name: introduction of lefamulin anti-infective into peripheral vein, percutaneous approach


name: introduction of ceftolozane/tazobactam anti-infective into peripheral vein, percutaneous approach


name: introduction of cefiderocol anti-infective into peripheral vein, percutaneous approach


name: introduction of omadacycline anti-infective into peripheral vein, percutaneous approach


name: introduction of remdesivir anti-infective into peripheral vein, percutaneous approach


name: introduction of cefepime-taniborbactam anti-infective into peripheral vein, percutaneous approach


name: introduction of sulbactam-durlobactam into peripheral vein


name: introduction of rezafungin into peripheral vein


name: introduction of trilaciclib into peripheral vein


name: introduction of brexanolone into peripheral vein


name: introduction of nerinetide into peripheral vein


name: introduction of terlipressin into peripheral vein


name: introduction of coagulation factor Xa, inactivated into peripheral vein


name: introduction of donislecel-jujn allogeneic pancreatic islet cellular suspension into peripheral vein


name: introduction of caplacizumab into peripheral vein


name: introduction of immunotherapy into peripheral vein


name: introduction of afamitresgene autoleucel into peripheral vein


name: NAA with probe detection for Haemophilus influenzae DNA in nasopharynx


name: NAA with probe detection for Chlamydophila pneumoniae DNA in bronchoalveolar lavage


name: NAA with probe detection for Mycoplasma pneumoniae DNA in bronchoalveolar lavage


name: NAA with probe detection for rhinovirus RNA in bronchoalveolar lavage


name: NAA with probe detection for rhinovirus RNA in bronchial specimen


name: NAA with probe detection for rhinovirus RNA in sputum


name: NAA with probe detection for influenza virus A RNA in bronchial specimen


name: NAA with probe detection for influenza virus A RNA in sputum


name: NAA with probe detection for respiratory syncytial virus RNA in bronchial specimen


name: NAA with probe detection for respiratory syncytial virus RNA in sputum


name: NAA with probe detection for respiratory syncytial virus A RNA in bronchial specimen


name: NAA with probe detection for respiratory syncytial virus A RNA in bronchoalveolar lavage


name: NAA with probe detection for respiratory syncytial virus B RNA in bronchial specimen


name: NAA with probe detection for respiratory syncytial virus B RNA in bronchoalveolar lavage


name: NAA with probe detection for influenza virus A+B RNA in bronchial specimen


name: NAA with probe detection for influenza virus A+B RNA in bronchoalveolar lavage


name: NAA with probe detection for influenza virus A+B RNA in sputum


name: introduction of ceftobiprole medocaril into peripheral vein


name: NAA with probe detection for influenza virus B RNA in bronchial specimen


name: introduction of spesolimab into central vein


name: NAA with probe detection for influenza virus B RNA in sputum


name: introduction of narsoplimab into central vein


name: introduction of amivantamab into central vein


name: introduction of bamlanivimab into central vein


name: introduction of REGN-COV2 into central vein


name: introduction of etesevimab into central vein


name: blood hematocrit level, post dose glucose


name: introduction of eculizumab into central vein


name: blood hematocrit level, 30 minutes post dose glucose


name: blood hematocrit level, 1 hour post dose glucose


name: blood hematocrit level, 1.5 hours post dose glucose


name: blood hematocrit level, 2 hours post dose glucose


name: blood hematocrit level, 2.5 hours post dose glucose


name: blood hematocrit level, 3 hours post dose glucose


name: introduction of sarilumab into central vein


name: multisection CT scan of spine for bone density


name: multisection CT scan of hip for bone density


name: multisection CT scan of hip for bone density, T-score


name: multisection CT scan of hip for bone density, Z-score


name: multisection CT scan of femur for bone density


name: introduction of inebilizumab-cdon into central vein


name: introduction of bentracimab, ticagrelor reversal agent into central vein


name: introduction of antineoplastic into central vein


name: introduction of durvalumab into central vein


name: introduction of mosunetuzumab into central vein


name: narrow thoracic cavity with constriction


name: narrow thoracic cavity without constriction


name: SLC12A1 variant of uncertain significance


name: CLCNKB variant of uncertain significance


name: CLCNKA variant of uncertain significance


name: MAGED2 variant of uncertain significance


name: SLC12A3 variant of uncertain significance


name: introduction of odronextamab into central vein


name: introduction of zanidatamab into central vein


name: introduction of atezolizumab into central vein


name: introduction of glofitamab into central vein


name: introduction of tagraxofusp-erzs into central vein


name: introduction of iobenguane I-131 into central vein


name: introduction of cytarabine and daunorubicin into central vein


name: introduction of treosulfan into central vein


name: introduction of lurbinectedin into central vein


name: introduction of ciltacabtagene autoleucel into central vein


name: introduction of anti-infective into central vein


name: introduction of lefamulin into central vein


name: introduction of ceftolozane and tazobactam into central vein


name: introduction of cefiderocol into central vein


name: introduction of omadacycline into central vein


name: introduction of remdesivir into central vein


name: introduction of cefepime-taniborbactam into central vein


name: introduction of sulbactam-durlobactam into central vein


name: introduction of rezafungin into central vein


name: introduction of ceftobiprole medocaril into central vein


name: introduction of immunotherapy into central vein


name: introduction of afamitresgene autoleucel into central vein


name: introduction of tabelecleucel into central vein


name: introduction of Orca-T into central vein


name: introduction of axicabtagene ciloleucel into central vein


name: introduction of tisagenlecleucel into central vein


name: introduction of lifileucel into central vein


name: introduction of autologous chimeric antigen receptor T-cell therapy into central vein


name: introduction of idecabtagene vicleucel into central vein


name: introduction of brexucabtagene autoleucel into central vein


name: introduction of lisocabtagene maraleucel into central vein


name: introduction of allogeneic chimeric antigen receptor T-cell therapy into central vein


name: introduction of obecabtagene autoleucel into central vein


name: introduction of posoleucel into central vein


name: introduction of CD24Fc into central vein


name: introduction of non-chimeric antigen receptor T-cell immune effector cell therapy into central vein


name: introduction of tocilizumab into central vein


name: Functional Assessment Staging Test (FAST)


name: lumbosacral arthrodesis with facet joint fusion device


name: introduction of anti-infective into mouth and pharynx


name: introduction of maribavir into mouth and pharynx


name: introduction of lefamulin into mouth and pharynx


name: introduction of SER-109 into mouth and pharynx


name: introduction of uridine triacetate into mouth and pharynx


name: introduction of quizartinib into mouth and pharynx


name: introduction of sabizabulin into mouth and pharynx


name: introduction of baricitinib into mouth and pharynx


name: introduction of fostamatinib into mouth and pharynx


name: multisection CT scan of femur for bone density, T-score


name: multisection CT scan of femur for bone density, Z-score


name: NAA with probe detection for Neisseria gonorrhoeae DNA in semen


name: NAA with probe detection for Mycobacterium tuberculosis DNA in stool


name: NAA with probe detection for Mycoplasma genitalium DNA in semen


name: NAA with probe detection for Varicella zoster virus DNA in genital specimen


name: NAA with probe detection for Trichomonas vaginalis DNA in semen


name: NAA with probe detection for Chlamydia trachomatis DNA in peritoneal fluid


name: NAA with probe detection for Candida spp. 1 DNA in positive blood culture


name: NAA with probe detection for Candida spp. 2 DNA in positive blood culture


name: NAA with probe detection for Aspergillus clavatus DNA


name: NAA with probe detection for Aspergillus flavus DNA


name: NAA with probe detection for Aspergillus niger DNA


name: introduction of tabelecleucel into peripheral vein


name: introduction of Orca-T allogeneic T-cell into peripheral vein


name: introduction of axicabtagene ciloleucel into peripheral vein


name: introduction of tisagenlecleucel into peripheral vein


name: introduction of lifileucel into peripheral vein


name: introduction of engineered chimeric antigen receptor T-cell immunotherapy, allogeneic into peripheral vein


name: introduction of idecabtagene vicleucel into peripheral vein


name: introduction of brexucabtagene autoleucel into peripheral vein


name: introduction of lisocabtagene maraleucel into peripheral vein


name: introduction of engineered chimeric antigen receptor T-cell immunotherapy, autologous into peripheral vein


name: introduction of obecabtagene autoleucel into peripheral vein


name: introduction of posoleucel into peripheral vein


name: introduction of CD24Fc immunomodulator into peripheral vein


name: introduction of non-chimeric antigen receptor T-cell immune effector cell therapy into peripheral vein


name: introduction of tocilizumab into peripheral vein


name: introduction of spesolimab into peripheral vein


name: introduction of narsoplimab into peripheral vein


name: introduction of amivantamab into peripheral vein


name: introduction of bamlanivimab into peripheral vein


name: introduction of REGN-COV2 into peripheral vein


name: introduction of etesevimab into peripheral vein


name: introduction of eculizumab into peripheral vein


name: introduction of sarilumab into peripheral vein


name: introduction of inebilizumab-cdon into peripheral vein


name: introduction of bentracimab, ticagrelor reversal agent into peripheral vein


name: NAA with probe detection for human bocavirus DNA in nasopharynx


name: NAA with probe detection for Bordetella pertussis DNA in bronchoalveolar lavage


name: NAA with probe detection for Bordetella parapertussis DNA in bronchoalveolar lavage


name: NAA with probe detection for Bordetella parapertussis DNA in lower respiratory specimen


name: NAA with probe detection for Legionella pneumophila DNA in nasopharynx


name: NAA with probe detection for parechovirus RNA in nasopharynx


name: MR angiography of aortic arch with IV contrast


name: beta-amyloid 1-42 and 1-40 panel in cerebrospinal fluid


name: rheumatoid factor IgM and IgA antibody panel in serum or plasma


name: primary biliary cholangitis comprehensive antibody panel in serum or plasma


name: measles, mumps, rubella and varicella-zoster virus IgG antibody panel in serum or plasma


name: CT scan of cervical spine during surgery


name: NAA with probe detection for parainfluenza virus RNA in bronchial specimen


name: NAA with probe detection for parainfluenza virus RNA in bronchoalveolar lavage


name: NAA with probe detection for parainfluenza virus RNA in sputum


name: insertion of radioactive element into head


name: drainage of oral cavity and throat with drainage device


name: supplement of right seminal vesicle with autologous tissue substitute


name: supplement of right seminal vesicle with synthetic substitute


name: supplement of right seminal vesicle with nonautologous tissue substitute


name: supplement of left seminal vesicle with autologous tissue substitute


name: supplement of left seminal vesicle with synthetic substitute


name: supplement of left seminal vesicle with nonautologous tissue substitute


name: supplement of seminal vesicles bilaterally with autologous tissue substitute


name: supplement of seminal vesicles bilaterally with synthetic substitute


name: supplement of seminal vesicles bilaterally with nonautologous tissue substitute


name: supplement of scrotum with autologous tissue substitute


name: supplement of scrotum with synthetic substitute


name: supplement of scrotum with nonautologous tissue substitute


name: supplement of right tunica vaginalis with autologous tissue substitute


name: supplement of right tunica vaginalis with synthetic substitute


name: supplement of right tunica vaginalis with nonautologous tissue substitute


name: supplement of left tunica vaginalis with autologous tissue substitute


name: supplement of left tunica vaginalis with synthetic substitute


name: supplement of left tunica vaginalis with nonautologous tissue substitute


name: dilation of pulmonary trunk with intraluminal device


name: dilation of pulmonary trunk with intraluminal device,


name: dilation of right pulmonary artery with intraluminal device


name: supplement of right spermatic cord with autologous tissue substitute


name: dilation of right pulmonary artery with intraluminal device, drug-eluting


name: dilation of left pulmonary artery with intraluminal device


name: supplement of right spermatic cord with synthetic substitute


name: dilation of left pulmonary artery with intraluminal device, drug-eluting


name: supplement of right spermatic cord with nonautologous tissue substitute


name: dilation of right pulmonary vein with intraluminal device


name: dilation of right pulmonary vein with intraluminal device, drug-eluting


name: dilation of left pulmonary vein with intraluminal device


name: dilation of left pulmonary vein with intraluminal device, drug-eluting


name: dilation of superior vena cava with intraluminal device


name: dilation of superior vena cava with intraluminal device, drug-eluting


name: dilation of descending thoracic aorta with intraluminal device


name: dilation of descending thoracic aorta with intraluminal device, drug-eluting


name: supplement of left spermatic cord with autologous tissue substitute


name: supplement of left spermatic cord with synthetic substitute


name: supplement of left spermatic cord with nonautologous tissue substitute


name: supplement of spermatic cords bilaterally with autologous tissue substitute


name: supplement of spermatic cords bilaterally with synthetic substitute


name: supplement of spermatic cords bilaterally with nonautologous tissue substitute


name: supplement of right epididymis with autologous tissue substitute


name: supplement of right epididymis with synthetic substitute


name: supplement of right epididymis with nonautologous tissue substitute


name: dilation of ascending/arch thoracic aorta


name: dilation of ascending/arch thoracic aorta with intraluminal device


name: dilation of ascending/arch thoracic aorta with intraluminal device, drug-eluting


name: fragmentation of solid matter in pelvic cavity


name: fragmentation of solid matter in gastrointestinal tract


name: fragmentation of solid matter in respiratory tract


name: fragmentation of solid matter in genitourinary tract


name: revision of drainage device in upper vein


name: revision of monitoring device in upper vein


name: revision of infusion device in upper vein


name: revision of autologous tissue substitute in upper vein


name: revision of extraluminal device in upper vein


name: revision of intraluminal device in upper vein


name: revision of synthetic substitute in upper vein


name: revision of nonautologous tissue substitute in upper vein


name: revision of monitoring device in azygos vein


name: revision of neurotransmitter lead in azygos vein


name: supplement of autologous tissue substitute of upper vein


name: supplement of synthetic substitute of upper vein


name: supplement of nonautologous tissue substitute of upper vein


name: x-ray of condyloid process of mandible, posteroanterior


name: supplement of left epididymis with autologous tissue substitute


name: supplement of left epididymis with synthetic substitute


name: supplement of left epididymis with nonautologous tissue substitute


name: supplement of epididymis bilaterally with autologous tissue substitute


name: supplement of epididymis bilaterally with synthetic substitute


name: supplement of epididymis bilaterally with nonautologous tissue substitute


name: insertion of radioactive element into right pleural cavity


name: insertion of infusion device into right pleural cavity


name: insertion of other device into right pleural cavity


name: insertion of radioactive element into left pleural cavity


name: insertion of infusion device into left pleural cavity


name: insertion of other device into left pleural cavity


name: insertion of radioactive element into mediastinum


name: insertion of infusion device into mediastinum


name: insertion of defibrillator lead into mediastinum


name: insertion of other device into mediastinum


name: insertion of device into pericardial cavity


name: insertion of radioactive element into pericardial cavity


name: insertion of infusion device into pericardial cavity


name: insertion of other device into pericardial cavity


name: insertion of radioactive element into face


name: insertion of device into oral cavity and throat


name: insertion of radioactive element into oral cavity and throat


name: insertion of infusion device into oral cavity and throat


name: insertion of other device into oral cavity and throat


name: insertion of radioactive element into upper jaw


name: insertion of infusion device into upper jaw


name: insertion of other device into upper jaw


name: insertion of radioactive element into lower jaw


name: insertion of infusion device into lower jaw


name: insertion of other device into lower jaw


name: insertion of radioactive element into neck


name: insertion of radioactive element into chest wall


name: insertion of infusion device into chest wall


name: insertion of other device into chest wall


name: Functional Assessment Staging Test (FAST) stage


name: patient's full name used for identification


name: patient's date of birth used for identification


name: patient's address used for identification


name: patient's phone number used for identification


name: dilation of right internal iliac artery with intraluminal device


name: dilation of right internal iliac artery with intraluminal device using drug-coated balloon


name: dilation of right internal iliac artery with intraluminal device, drug-eluting


name: dilation of right internal iliac artery with intraluminal device, drug-eluting using drug-coated balloon


name: dilation of left internal iliac artery with intraluminal device


name: dilation of left internal iliac artery with intraluminal device using drug-coated balloon


name: dilation of left internal iliac artery with intraluminal device, drug-eluting


name: dilation of left internal iliac artery with intraluminal device, drug-eluting using drug-coated balloon


name: dilation of right external iliac artery using drug-coated balloon


name: bypass spinal canal to atrium with autologous tissue substitute


name: bypass spinal canal to atrium with synthetic substitute


name: bypass spinal canal to atrium with nonautologous tissue substitute


name: bypass spinal canal to pleural cavity with autologous tissue substitute


name: bypass spinal canal to pleural cavity with synthetic substitute


name: bypass spinal canal to pleural cavity with nonautologous tissue substitute


name: bypass spinal canal to peritoneal cavity


name: bypass spinal canal to peritoneal cavity with autologous tissue substitute


name: bypass spinal canal to peritoneal cavity with synthetic substitute


name: bypass spinal canal to peritoneal cavity with nonautologous tissue substitute


name: bypass spinal canal to urinary tract with autologous tissue substitute


name: bypass spinal canal to urinary tract with synthetic substitute


name: bypass spinal canal to urinary tract with nonautologous tissue substitute


name: bypass spinal canal to fallopian tube with autologous tissue substitute


name: bypass spinal canal to fallopian tube with synthetic substitute


name: patient identifier - government-issued ID


name: bypass spinal canal to fallopian tube with nonautologous tissue substitute


name: patient identifier - assigned identification number


name: patient's insurance card used for identification


name: patient's identity verified by family/caregiver


name: patient identification verified verbally


name: patient identification verified visually


name: patient identification verified electronically


name: confirmation of patient verification not required


name: confirmation of patient verification by staff


name: confirmation of patient verification by second staff member


name: two identifiers confirmed for patient verification


name: dilation of left external iliac artery using drug-coated balloon


name: Safe Environment for Every Kid parent questionnaire


name: x-ray of cervical esophagus with contrast


name: CT arthrogram of midtarsal joint without contrast


name: CT arthrogram of midtarsal joint without and with contrast


name: CT arthrogram of subtalar joint without contrast


name: CT arthrogram of subtalar joint without and with contrast


name: x-ray of orbit without and with contrast


name: x-ray of nasopharynx without and with contrast


name: drainage of upper jaw with drainage device


name: drainage of lower jaw with drainage device


name: revision of synthetic substitute in right shoulder joint


name: revision of synthetic substitute in right shoulder joint, humeral surface


name: revision of synthetic substitute in right shoulder joint, glenoid surface


name: revision of drainage device in right shoulder joint


name: revision of infusion device in right shoulder joint


name: revision of internal fixation device in right shoulder joint


name: revision of autologous tissue substitute in right shoulder joint


name: revision of spacer in right shoulder joint


name: revision of nonautologous tissue substitute in right shoulder joint


name: bypass cerebral ventricle to nasopharynx


name: bypass cerebral ventricle to nasopharynx with autologous tissue substitute


name: bypass cerebral ventricle to nasopharynx with synthetic substitute


name: bypass cerebral ventricle to nasopharynx with nonautologous tissue substitute


name: bypass cerebral ventricle to mastoid sinus


name: bypass cerebral ventricle to mastoid sinus with autologous tissue substitute


name: bypass cerebral ventricle to mastoid sinus with nonautologous tissue substitute


name: bypass cerebral ventricle to mastoid sinus with synthetic substitute


name: bypass cerebral ventricle to atrium with autologous tissue substitute


name: bypass cerebral ventricle to atrium with nonautologous tissue substitute


name: bypass cerebral ventricle to atrium with synthetic substitute


name: bypass cerebral ventricle to blood vessel


name: bypass cerebral ventricle to blood vessel with autologous tissue substitute


name: bypass cerebral ventricle to blood vessel with nonautologous tissue substitute


name: bypass cerebral ventricle to blood vessel with synthetic substitute


name: bypass cerebral ventricle to pleural cavity


name: bypass cerebral ventricle to pleural cavity with autologous tissue substitute


name: bypass cerebral ventricle to pleural cavity with synthetic substitute


name: bypass cerebral ventricle to pleural cavity with nonautologous tissue substitute


name: bypass cerebral ventricle to intestine with autologous tissue substitute


name: bypass cerebral ventricle to intestine with synthetic substitute


name: bypass cerebral ventricle to intestine with nonautologous tissue substitute


name: bypass cerebral ventricle to peritoneal cavity


name: bypass cerebral ventricle to peritoneal cavity with autologous tissue substitute


name: bypass cerebral ventricle to peritoneal cavity with synthetic substitute


name: bypass cerebral ventricle to peritoneal cavity with nonautologous tissue substitute


name: bypass cerebral ventricle to urinary tract


name: bypass cerebral ventricle to urinary tract with autologous tissue substitute


name: bypass cerebral ventricle to urinary tract with synthetic substitute


name: bypass cerebral ventricle to urinary tract with nonautologous tissue substitute


name: bypass cerebral ventricle to bone marrow


name: bypass cerebral ventricle to bone marrow with autologous tissue substitute


name: bypass cerebral ventricle to bone marrow with synthetic substitute


name: bypass cerebral ventricle to bone marrow with nonautologous tissue substitute


name: bypass cerebral ventricle to subgaleal space


name: bypass cerebral ventricle to subgaleal space with autologous tissue substitute


name: bypass cerebral ventricle to subgaleal space with synthetic substitute


name: bypass cerebral ventricle to subgaleal space with nonautologous tissue substitute


name: bypass cerebral ventricle to cerebral cisterns


name: bypass cerebral ventricle to cerebral cisterns with autologous tissue substitute


name: bypass cerebral ventricle to cerebral cisterns with synthetic substitute


name: bypass cerebral ventricle to cerebral cisterns with nonautologous tissue substitute


name: VTSL USDA Veterinary Services organism reference set


name: Specimen from tonsil and oral cavity obtained by scraping


name: bilateral MRI of sacroiliac joints without and with contrast


name: MRI of left sacroiliac joint without and with contrast


name: Allopathic & Osteopathic Physicians; Anesthesiology, Physician Nutrition Specialist


name: Allopathic & Osteopathic Physicians; Family Medicine, Physician Nutrition Specialist


name: Allopathic & Osteopathic Physicians; Internal Medicine, Physician Nutrition Specialist


name: Allopathic & Osteopathic Physicians; Pediatrics, Physician Nutrition Specialist


name: Allopathic & Osteopathic Physicians; Surgery, Physician Nutrition Specialist


name: Resolve matrix or xenopatch, per square centimeter (add-on, list separately in addition to primary procedure)


name: Matriderm, per square centimeter (add-on, list separately in addition to primary procedure)


name: Mirotract wound matrix sheet, per cubic centimeter (add-on, list separately in addition to primary procedure)


name: Integrated lancing and blood sample testing cartridges for home blood glucose monitor, per 50 tests


name: Adhesive clip applied to the skin to secure external electrical nerve stimulator controller, each


name: Supplies for transcutaneous electrical nerve stimulator, for nerves in the auricular region, per month


name: Electrode for external lower extremity nerve stimulator for restless legs syndrome


name: Supplies and accessories for external tibial nerve stimulator (e.g., socks, gel pads, electrodes, etc.), needed for one month


name: Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, controller


name: Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, mouthpiece each


name: Supplies and accessories for lung expansion airway clearance, continuous high frequency oscillation, and nebulization device (e.g., handset, nebulizer kit, biofilter)


name: Fertility cycle (contraception & conception) tracking software application, fda cleared, per month, includes accessories (e.g., thermometer)


name: Graphite crucible for preparation of technetium tc 99m-labeled carbon aerosol, one crucible


name: Pacemaker, leadless, dual chamber (right atrial and right ventricular implantable components), rate-responsive, including all necessary components for implantation


name: Adapter, single-use (i.e. disposable), for attaching ultrasound system to upper gastrointestinal endoscope


name: Catheter(s), intravascular for renal denervation, radiofrequency, including all single use system components


name: Catheter(s), intravascular for renal denervation, ultrasound, including all single use system components


name: Joint fusion and fixation device(s), sacroiliac and pelvis, including all system components (implantable)


name: Powered, single-use (i.e. disposable) endoscopic ultrasound-guided biopsy device


name: Tissue marker, uniquely detectable and identifiable with probe/sensor, any method (implantable), with delivery system


name: Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed with intraprocedural coronary fractional flow reserve (ffr) with 3d functional mapping of color-coded ffr values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention


name: Transluminal balloon angioplasty (except lower extremity artery(ies) for occlusive disease, intracranial, coronary, pulmonary, or dialysis circuit), open or percutaneous, including all imaging and radiological supervision and interpretation necessary to perform the angioplasty within the same artery, initial artery and all additional arteries


name: Percutaneous transluminal mechanical thrombectomy, vein(s), including intraprocedural pharmacological thrombolytic injections and fluoroscopic guidance with intravascular ultrasound (noncoronary vessel(s)) during diagnostic evaluation and/or therapeutic intervention, including radiological supervision and interpretation


name: Repair of anterior abdominal hernia(s) (ie, epigastric, incisional, ventral, umbilical, spigelian), any approach (i.e., open, laparoscopic, robotic), recurrent, including implantation of mesh or other prosthesis when performed, total length of defect(s) less than 3 cm, reducible with removal of total or near total non-infected mesh or other prosthesis at the time of initial or recurrent anterior abdominal hernia repair or parastomal hernia repair


name: Support device, extravascular, for arteriovenous fistula (implantable)


name: 3d anatomical segmentation imaging for preoperative planning, data preparation and transmission, obtained from previous diagnostic computed tomographic or magnetic resonance examination of the same anatomy


name: Preparation of skin cell suspension autograft, automated, including all enzymatic processing and device components (do not report with manual suspension preparation)


name: Implantation of medial knee extraarticular implantable shock absorber spanning the knee joint from distal femur to proximal tibia, open, includes measurements, positioning and adjustments, with imaging guidance (e.g., fluoroscopy)


name: Catheter, transluminal drug delivery with or without angioplasty, coronary, non-laser (insertable)


name: Repair of enterocutaneous fistula small intestine or colon (excluding anorectal fistula) with plug (e.g., porcine small intestine submucosa [sis])


name: Vascular embolization or occlusion procedure with use of a pressure-generating catheter (e.g., one-way valve, intermittently occluding), inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction


name: Elastomeric infusion pump (e.g., on-q* pump with bolus), including catheter and all disposable system components, non-opioid medical device (must be a qualifying medicare non-opioid medical device for post-surgical pain relief in accordance with section 4135 of the caa, 2023)


name: Rotary peristaltic infusion pump (e.g., ambit pump), including catheter and all disposable system components, non-opioid medical device (must be a qualifying medicare non-opioid medical device for post-surgical pain relief in accordance with section 4135 of the caa, 2023)


name: Nerve stimulator, percutaneous, peripheral (e.g., sprint peripheral nerve stimulation system), including electrode and all disposable system components, non-opioid medical device (must be a qualifying medicare non-opioid medical device for post-surgical pain relief in accordance with section 4135 of the caa, 2023)


name: Nerve cryoablation probe (e.g., cryoice, cryosphere, cryosphere max, cryoice cryosphere, cryoice cryo2), including probe and all disposable system components, non-opioid medical device (must be a qualifying medicare non-opioid medical device for post-surgical pain relief in accordance with section 4135 of the caa, 2023)


name: Cryoablation needle (e.g., iovera system), including needle/tip and all disposable system components, non-opioid medical device (must be a qualifying medicare non-opioid medical device for post-surgical pain relief in accordance with section 4135 of the caa, 2023)


name: Endoscopic defect closure within the entire gastrointestinal tract, including upper endoscopy (including diagnostic, if performed) or colonoscopy (including diagnostic, if performed), with all system and tissue anchoring components


name: Walker, battery powered, wheeled, folding, adjustable or fixed height


name: Home ventilator, dual-function respiratory device, also performs additional function of cough stimulation, includes all accessories, components and supplies for all functions


name: Lung expansion airway clearance, continuous high frequency oscillation, and nebulization device


name: Non-pneumatic, non-sequential, peristaltic wave compression pump


name: Intravaginal device intended to strengthen pelvic floor muscles during kegel exercises


name: Supplies and accessories for intravaginal device intended to strengthen pelvic floor muscles during kegel exercises


name: Transcutaneous electrical nerve stimulator for nerves in the auricular region


name: Transcutaneous tibial nerve stimulator, controlled by phone application


name: Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education, include microprocessor, all components and accessories


name: Rehabilitation system with interactive interface providing active assistance in rehabilitation therapy, includes all components and accessories, motors, microprocessors, sensors


name: External lower extremity nerve stimulator for restless legs syndrome, each


name: Intrabuccal, systemic delivery of amplitude-modulated, radiofrequency electromagnetic field device, for cancer treatment, includes all accessories


name: Dynamic adjustable elbow extension only device, includes soft interface material


name: Dynamic adjustable elbow flexion only device, includes soft interface material


name: Dynamic adjustable wrist extension only device, includes soft interface material


name: Dynamic adjustable wrist flexion only device, includes soft interface material


name: Dynamic adjustable knee extension only device, includes soft interface material


name: Dynamic adjustable knee flexion only device, includes soft interface material


name: Dynamic adjustable ankle extension only device, includes soft interface material


name: Dynamic adjustable ankle flexion only device, includes soft interface material


name: Dynamic adjustable finger extension only device, includes soft interface material


name: Dynamic adjustable finger flexion only device, includes soft interface material


name: Dynamic adjustable toe extension only device, includes soft interface material


name: Dynamic adjustable toe flexion only device, includes soft interface material


name: Suction pump, home model, portable or stationary, electric, any type, for use with external urine and/or fecal management system


name: Home blood glucose monitor for use with integrated lancing/blood sample testing cartridge


name: Complex rehabilitative power wheelchair accessory, power seat elevation system, any type


name: Accessory for speech generating device, electromyographic sensor


name: Gait modulation system, rhythmic auditory stimulation, including restricted therapy software, all components and accessories, prescription only


name: Intravenous infusion of cipaglucosidase alfa-atga, including provider/supplier acquisition and clinical supervision of oral administration of miglustat in preparation of receipt of cipaglucosidase alfa-atga


name: Management of new patient-caregiver dyad with dementia, low complexity, for use in cmmi model


name: Management of new patient-caregiver dyad with dementia, moderate complexity, for use in cmmi model


name: Management of new patient-caregiver dyad with dementia, high complexity, for use in cmmi model


name: Management of a new patient with dementia, low complexity, for use in cmmi model


name: Management of a new patient with dementia, moderate to high complexity, for use in cmmi model


name: Management of established patient-caregiver dyad with dementia, low complexity, for use in cmmi model


name: Management of established patient-caregiver dyad with dementia, moderate complexity, for use in cmmi model


name: Management of established patient-caregiver dyad with dementia, high complexity, for use in cmmi model


name: Management of established patient with dementia, low complexity, for use in cmmi model


name: Management of established patient with dementia, moderate to high complexity, for use in cmmi model


name: In-home respite care, 4-hour unit, for use in cmmi model


name: Adult day center, 8-hour unit, for use in cmmi model


name: Facility-based respite, 24-hour unit, for use in cmmi model


name: Take-home supply of nasal nalmefene hydrochloride; one carton of two, 2.7 mg per 0.1 ml nasal sprays (provision of the services by a medicare-enrolled opioid treatment program);( list separately in addition to each primary code)


name: Medication assisted treatment, buprenorphine (injectable) administered on a weekly basis; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program)


name: Coordinated care and/or referral services, such as to adequate and accessible community resources to address unmet health-related social needs, including harm reduction interventions and recovery support services a patient needs and wishes to pursue, which significantly limit the ability to diagnose or treat an opioid use disorder; each additional 30 minutes of services (provision of the services by a medicare-enrolled opioid treatment program); (list separately in addition to each primary code)


name: Patient navigational services, provided directly or by referral; including helping the patient to navigate health systems and identify care providers and supportive services, to build patient self-advocacy and communication skills with care providers, and to promote patient-driven action plans and goals; each additional 30 minutes of services (provision of the services by a medicare-enrolled opioid treatment program); (list separately in addition to each primary code)


name: Peer recovery support services, provided directly or by referral; including leveraging knowledge of the condition or lived experience to provide support, mentorship, or inspiration to meet oud treatment and recovery goals; conducting a person-centered interview to understand the patient's life story, strengths, needs, goals, preferences, and desired outcomes; developing and proposing strategies to help meet person-centered treatment goals; assisting the patient in locating or navigating recovery support services; each additional 30 minutes of services (provision of the services by a medicare-enrolled opioid treatment program); (list separately in addition to each primary code)


name: Administration of a standardized, evidence-based atherosclerotic cardiovascular disease (ascvd) risk assessment, 5-15 minutes, not more often than every 12 months


name: Atherosclerotic cardiovascular disease (ascvd) risk management services; clinical staff time; per calendar month


name: Caregiver training in behavior management/modification for caregiver(s) of patients with a mental or physical health diagnosis, administered by physician or other qualified health care professional (without the patient present), face-to-face; initial 30 minutes


name: Caregiver training in behavior management/modification for parent(s)/guardian(s)/caregiver(s) of patients with a mental or physical health diagnosis, administered by physician or other qualified health care professional (without the patient present), face-to-face; each additional 15 minutes


name: Caregiver training in direct care strategies and techniques to support care for patients with an ongoing condition or illness and to reduce complications (including, but not limited to, techniques to prevent decubitus ulcer formation, wound care, and infection control) (without the patient present), face-to-face; initial 30 minutes


name: Caregiver training in direct care strategies and techniques to support care for patients with an ongoing condition or illness and to reduce complications (including, but not limited to, techniques to prevent decubitus ulcer formation, wound care, and infection control) (without the patient present), face-to-face; each additional 15 minutes (list separately in addition to code for primary service) (use g0542 in conjunction with g0541)


name: Group caregiver training in direct care strategies and techniques to support care for patients with an ongoing condition or illness and to reduce complications (including, but not limited to, techniques to prevent decubitus ulcer formation, wound care, and infection control) (without the patient present), face-to-face with multiple sets of caregivers


name: Post discharge telephonic follow-up contacts performed in conjunction with a discharge from the emergency department for behavioral health or other crisis encounter, 4 calls per calendar month


name: Visit complexity inherent to hospital inpatient or observation care associated with a confirmed or suspected infectious disease by an infectious diseases specialist, including disease transmission risk assessment and mitigation, public health investigation, analysis, and testing, and complex antimicrobial therapy counseling and treatment (add-on code, list separately in addition to hospital inpatient or observation evaluation and management visit, initial, same day discharge, subsequent or discharge)


name: Interprofessional telephone/internet/electronic health record assessment and management service provided by a practitioner in a specialty whose covered services are limited by statute to services for the diagnosis and treatment of mental illness, including a verbal and written report to the patient's treating/requesting practitioner; 5-10 minutes of medical consultative discussion and review


name: Interprofessional telephone/internet/electronic health record assessment and management service provided by a practitioner in a specialty whose covered services are limited by statute to services for the diagnosis and treatment of mental illness, including a verbal and written report to the patient's treating/requesting practitioner; 11-20 minutes of medical consultative discussion and review


name: Interprofessional telephone/internet/electronic health record assessment and management service provided by a practitioner in a specialty whose covered services are limited by statute to services for the diagnosis and treatment of mental illness, including a verbal and written report to the patient's treating/requesting practitioner; 21-30 minutes of medical consultative discussion and review


name: Interprofessional telephone/internet/electronic health record assessment and management service provided by a practitioner in a specialty whose covered services are limited by statute to services for the diagnosis and treatment of mental illness, including a verbal and written report to the patient's treating/requesting practitioner; 31 or more minutes of medical consultative discussion and review


name: Interprofessional telephone/internet/electronic health record assessment and management service provided by a practitioner in a specialty whose covered services are limited by statute to services for the diagnosis and treatment of mental illness, including a written report to the patient's treating/requesting practitioner, 5 minutes or more of medical consultative time


name: Interprofessional telephone/internet/electronic health record referral service(s) provided by a treating/requesting practitioner in a specialty whose covered services are limited by statute to services for the diagnosis and treatment of mental illness, 30 minutes


name: Supply of digital mental health treatment device and initial education and onboarding, per course of treatment that augments a behavioral therapy plan


name: First 20 minutes of monthly treatment management services directly related to the patient's therapeutic use of the digital mental health treatment (dmht) device that augments a behavioral therapy plan, physician/other qualified health care professional time reviewing information related to the use of the dmht device, including patient observations and patient specific inputs in a calendar month and requiring at least one interactive communication with the patient/caregiver during the calendar month


name: Each additional 20 minutes of monthly treatment management services directly related to the patient's therapeutic use of the digital mental health treatment (dmht) device that augments a behavioral therapy plan, physician/other qualified health care professional time reviewing data generated from the dmht device from patient observations and patient specific inputs in a calendar month and requiring at least one interactive communication with the patient/caregiver during the calendar month


name: Provision of replacement patient electronics system (e.g., system pillow, handheld reader) for home pulmonary artery pressure monitoring


name: Advanced primary care management services for a patient with one chronic condition [expected to last at least 12 months, or until the death of the patient, which place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline], or fewer, provided by clinical staff and directed by a physician or other qualified health care professional who is responsible for all primary care and serves as the continuing focal point for all needed health care services, per calendar month


name: Advanced primary care management services for a patient with multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, which place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, provided by clinical staff and directed by a physician or other qualified health care professional who is responsible for all primary care and serves as the continuing focal point for all needed health care services, per calendar month


name: Advanced primary care management services for a patient that is a qualified medicare beneficiary with multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, which place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, provided by clinical staff and directed by a physician or other qualified health care professional who is responsible for all primary care and serves as the continuing focal point for all needed health care services, per calendar month


name: Post-operative follow-up visit complexity inherent to evaluation and management services addressing surgical procedure(s), provided by a physician or qualified health care professional who is not the practitioner who performed the procedure (or in the same group practice) and is of the same or of a different specialty than the practitioner who performed the procedure, within the 90-day global period of the procedure(s), once per 90-day global period, when there has not been a formal transfer of care and requires the following required elements, when possible and applicable: reading available surgical note to understand the relative success of the procedure, the anatomy that was affected, and potential complications that could have arisen due to the unique circumstances of the patient's operation. research the procedure to determine expected post-operative course and potential complications (in the case of doing a post-op for a procedure outside the specialty). evaluate and physically examine the patient to determine whether the post-operative course is progressing appropriately. communicate with the practitioner who performed the procedure if any questions or concerns arise. (list separately in addition to office/outpatient evaluation and management visit, new or established)


name: Safety planning interventions, each 20 minutes personally performed by the billing practitioner, including assisting the patient in the identification of the following personalized elements of a safety plan: recognizing warning signs of an impending suicidal or substance use-related crisis; employing internal coping strategies; utilizing social contacts and social settings as a means of distraction from suicidal thoughts or risky substance use; utilizing family members, significant others, caregivers, and/or friends to help resolve the crisis; contacting mental health or substance use disorder professionals or agencies; and making the environment safe


name: Tympanostomy with local or topical anesthesia and insertion of a ventilating tube when performed with tympanostomy tube delivery device, unilateral (list separately in addition to 69433) (do not use in conjunction with 0583t)


name: Apnea hypopnea index (ahi), respiratory disturbance index (rdi) or respiratory event index (rei) documented or measured within 2 months after initial evaluation for suspected obstructive sleep apnea


name: Documentation of reason(s) for not measuring an apnea hypopnea index (ahi), a respiratory disturbance index (rdi), or a respiratory event index (rei) within 2 months after initial evaluation for suspected obstructive sleep apnea (e.g., medical, neurological, or psychiatric disease that prohibits successful completion of a sleep study, patients for whom a sleep study would present a bigger risk than benefit or would pose an undue burden, dementia, patients previously diagnosed with osa and severity assessed by another provider, patients who decline ahi/rdi/rei measurement, patients who had a financial reason for not completing testing, test was ordered but not completed, patients decline because their insurance (payer) does not cover the expense)


name: Apnea hypopnea index (ahi), respiratory disturbance index (rdi), or respiratory event index (rei) not documented or measured within 2 months after initial evaluation for suspected obstructive sleep apnea, reason not given


name: Patient did not have two eligible encounters at least 90 days apart or one eligible encounter and one hiv viral load test at least 90 days apart


name: Patient had two eligible encounters at least 90 days apart or one eligible encounter and one hiv viral load test at least 90 days apart


name: Documentation of patient discharged to home no later than post operative day 2 following cea or cas


name: Count of previous ct (any type of ct) and cardiac nuclear medicine (myocardial perfusion or infarct avid imaging) studies documented in the 12-month period prior to the current study


name: Count of previous ct and cardiac nuclear medicine (myocardial perfusion or infarct avid imaging) studies not documented in the 12-month period prior to the current study, reason not given


name: Patients greater than or equal to 86 years of age who underwent a screening colonoscopy and did not have a history of colorectal cancer or other valid medical reason for the colonoscopy, including: iron deficiency anemia, lower gastrointestinal bleeding, familial adenomatous polyposis, lynch syndrome (i.e., hereditary non-polyposis colorectal cancer), inflammatory bowel disease (i.e., crohn's disease or ulcerative colitis), abnormal finding of gastrointestinal tract, weight loss, or changes in bowel habits


name: Documentation of medical reason(s) for a colonoscopy performed on a patient greater than or equal to 86 years of age (e.g., iron deficiency anemia, lower gastrointestinal bleeding, familial history of adenomatous polyposis, lynch syndrome (i.e., hereditary non-polyposis colorectal cancer), inflammatory bowel disease (i.e., crohn's disease or ulcerative colitis), abnormal finding of gastrointestinal tract, weight loss, or changes in bowel habits)


name: Missing and murdered indigenous persons (mmip) mental health and clinical care


name: Historical trauma (ht) mental health and clinical care for indigenous persons


name: Docking station for use with oral device/appliance used to reduce upper airway collapsibility


name: Scoliosis orthosis, sagittal-coronal control provided by a rigid lateral frame, extends from axilla to trochanter, includes all accessory pads, straps and interface, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise


name: Thoracic, pectus carinatum orthosis, sternal compression, rigid circumferential frame with anterior and posterior rigid pads, custom fabricated


name: Hip orthosis, bilateral thigh cuffs with adjustable abductor spreader bar, adult size, prefabricated, off the shelf


name: Knee orthosis, elastic with condylar pads and joints, with or without patellar control, prefabricated, off the shelf


name: Addition to lower extremity, user adjustable, mechanical, residual limb volume management system (with or without lamination kit)


name: Addition, endoskeletal knee-shin system, polycentric, pneumatic swing, and stance phase control


name: External lower extremity sensory prosthetic device, cutaneous stimulation of mechanoreceptors proximal to the ankle, per leg


name: Receptor sole for use with l8720, replacement, each


name: Quality care for patients with neurological conditions mips value pathway


name: Intravenous infusion, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, includes infusion and post administration monitoring


name: Patient did not receive two doses of the herpes zoster recombinant vaccine (at least 28 days apart) on october 20, 2017, through the end of the measurement period


name: Patient received any pneumococcal conjugate or polysaccharide vaccine on or after their 19th birthday and before the end of the measurement period (M1177)


name: Most recent glycemic status assessment (hba1c or gmi) level > 9.0%


name: Glycemic status assessment (hba1c or gmi) level is missing, or was not performed during the measurement period


name: Patient status documented within the first year of initiating dialysis


name: Patient status not documented within the first year of initiating dialysis


name: Patients who did not have a baseline pam score and/or a second score within 4 to 12 months of baseline pam score


name: Patients who had a baseline pam score and a second score within 4 to 12 month of baseline pam score


name: Patients who did not have a net increase in pam score of at least 6 points within a 4 to 12 month period


name: Patients who achieved a net increase in pam score of at least 3 points in a 4 to 12 month period (passing)


name: Patients who achieved a net increase in pam score of at least 6-points in a 4 to 12 month period (excellent)


name: Patients who did not have a net increase in pam score of at least 3 points within a 4 to 12 month period


name: Most recent glycemic status assessment (hba1c or gmi) level < 7.0%


name: Most recent glycemic status assessment (hba1c or gmi) level >= 7.0% and < 8.0%


name: Most recent glycemic status assessment (hba1c or gmi) level >= 8.0% and <= 9.0%


name: An additional encounter with an ra diagnosis during the performance period or prior performance period that is at least 90 days before or after an encounter with an ra diagnosis during the performance period (M1374)


name: An additional encounter with an ra diagnosis during the performance period or prior performance period that is at least 90 days before or after an encounter with an ra diagnosis during the performance period (M1375)


name: An additional encounter with an ra diagnosis during the performance period or prior performance period that is at least 90 days before or after an encounter with an ra diagnosis during the performance period (M1376)


name: Recommended follow-up interval for repeat colonoscopy of 10 years documented in colonoscopy report and communicated with patient


name: Documentation of medical reason(s) for not recommending a 10 year follow-up interval (e.g., inadequate prep, familial or personal history of colonic polyps, patient had no adenoma and age is >= 66 years old, or life expectancy < 10 years, other medical reasons)


name: A 10 year follow-up interval for colonoscopy not recommended, reason not otherwise specified


name: Filled at least two prescriptions during the performance period for any combination of the qualifying oral antipsychotic medications listed under "denominator note" or the long-acting injectable antipsychotic medications listed under "denominator note"


name: Patients with secondary stroke (e.g., a subsequent stroke that may occur with vasospasm in the setting of subarachnoid hemorrhage) within 5 days of the initial procedure


name: Patient encounter during the performance period with place of service code 11


name: Patients who died during the performance period (M1384)


name: Documentation of patient reasons for patients who were not seen for the second pam survey (e.g., less than four months between baseline pam assessment and follow-up


name: Patients with an excisional surgery for melanoma or melanoma in situ in the past 5 years with an initial ajcc staging of 0, i, or ii at the start of the performance period


name: Patients who died during the performance period (M1387)


name: Patients with documentation of an exam performed for recurrence of melanoma


name: Patients who do not have a documented exam performed for recurrence of melanoma or no documentation within the performance period


name: All patients who were diagnosed with recurrent melanoma during the current performance period


name: Documentation of patient reasons for no examination, i.e., refusal of examination or lost to follow-up (documentation must include information that the clinician was unable to reach the patient by phone, mail or secure electronic mail - at least one method must be documented)


name: Patients who were not diagnosed with recurrent melanoma during the current performance period


name: Patients receiving an initial chemotherapy regimen with a defined duration with the eligible clinician or group (M1395)


name: Patients on a therapeutic clinical trial (M1396)


name: Patients with recurrence/disease progression (M1397)


name: Patients with baseline and follow-up promis surveys documented in the medical record (M1398)


name: Patients who leave the practice during the follow-up period (M1399)


name: Patients who died during the follow-up period (M1400)


name: Patients receiving an initial chemotherapy regimen with a defined duration with the eligible clinician or group (M1402)


name: Patients with baseline and follow-up promis surveys documented in the medical record (M1403)


name: Patients on a therapeutic clinical trial (M1404)


name: Patients with recurrence/disease progression (M1405)


name: Patients who leave the practice during the follow-up period (M1406)


name: Patients who died during the follow-up period (M1407)


name: Patients who have germline brca testing completed before diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer


name: Patients who received germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis


name: Patients who did not have germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis


name: Currently on first-line immune checkpoint inhibitors without chemotherapy


name: Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement


name: Patients who had a positive pd-l1 biomarker expression test result prior to the initiation of first-line immune checkpoint inhibitor therapy


name: Documentation of medical reason(s) for not performing the pd-l1 biomarker expression test prior to initiation of first-line immune checkpoint inhibitor therapy (e.g., patient is in an urgent or emergent situation where delay of treatment would jeopardize the patient's health status; other medical reasons/contraindication)


name: Patients who did not have a positive pd-l1 biomarker expression test result prior to the initiation of first-line immune checkpoint inhibitor therapy


name: Patient received hospice services any time during the performance period


name: Patients who are up to date on their covid-19 vaccinations as defined by cdc recommendations on current vaccination


name: Patients who are not up to date on their covid-19 vaccinations as defined by cdc recommendations on current vaccination because of a medical contraindication documented by clinician


name: Patients who are not up to date on their covid-19 vaccinations as defined by cdc recommendations on current vaccination


name: Complete ophthalmologic care mips value pathway


name: Gastroenterology care mips value pathway


name: Optimal care for patients with urologic conditions mips value pathway


name: Red blood cells, leukocytes reduced, oxygen/ carbon dioxide reduced, each unit


name: Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription


name: American amnion ac tri-layer, per square centimeter (add-on, list separately in addition to primary procedure)


name: American amnion ac, per square centimeter (add-on, list separately in addition to primary procedure)


name: American amnion, per square centimeter (add-on, list separately in addition to primary procedure)


name: Sanopellis, per square centimeter (add-on, list separately in addition to primary procedure)


name: Via matrix, per square centimeter (add-on, list separately in addition to primary procedure)


name: Acesso, per square centimeter (add-on, list separately in addition to primary procedure)


name: Acesso ac, per square centimeter (add-on, list separately in addition to primary procedure)


name: Dermabind fm, per square centimeter (add-on, list separately in addition to primary procedure)


name: Reeva ft, per square cenitmeter (add-on, list separately in addition to primary procedure)


name: Regenelink amniotic membrane allograft, per square centimeter (add-on, list separately in addition to primary procedure)


name: Amchoplast, per square centimeter (add-on, list separately in addition to primary procedure)


name: Vitograft, per square centimeter (add-on, list separately in addition to primary procedure)


name: E-graft, per square centimeter (add-on, list separately in addition to primary procedure)


name: Sanograft, per square centimeter (add-on, list separately in addition to primary procedure)


name: Pellograft, per square centimeter (add-on, list separately in addition to primary procedure)


name: Renograft, per square centimeter (add-on, list separately in addition to primary procedure)


name: Caregraft, per square centimeter (add-on, list separately in addition to primary procedure)


name: Alloply, per square centimeter (add-on, list separately in addition to primary procedure)


name: Amniotx, per square centimeter (add-on, list separately in addition to primary procedure)


name: Acapatch, per square centimeter (add-on, list separately in addition to primary procedure)


name: Woundplus, per square centimeter (add-on, list separately in addition to primary procedure)


name: Duoamnion, per square centimeter (add-on, list separately in addition to primary procedure)


name: Most, per square centimeter (add-on, list separately in addition to primary procedure)


name: Singlay, per square centimeter (add-on, list separately in addition to primary procedure)


name: Total, per square centimeter (add-on, list separately in addition to primary procedure)


name: Axolotl graft, per square centimeter (add-on, list separately in addition to primary procedure)


name: Axolotl dualgraft, per square centimeter (add-on, list separately in addition to primary procedure)


name: Ardeograft, per square centimeter (add-on, list separately in addition to primary procedure)


name: Amnioplast 1, per square centimeter (add-on, list separately in addition to primary procedure)


name: Amnioplast 2, per square centimeter (add-on, list separately in addition to primary procedure)


name: Artacent c, per square centimeter (add-on, list separately in addition to primary procedure)


name: Artacent trident, per square centimeter (add-on, list separately in addition to primary procedure)


name: Artacent velos, per square centimeter (add-on, list separately in addition to primary procedure)


name: Artacent vericlen, per square centimeter (add-on, list separately in addition to primary procedure)


name: Simpligraft, per square centimeter (add-on, list separately in addition to primary procedure)


name: Simplimax, per square centimeter (add-on, list separately in addition to primary procedure)


name: Theramend, per square centimeter (add-on, list separately in addition to primary procedure)


name: Dermacyte ac matrix amniotic membrane allograft, per square centimeter (add-on, list separately in addition to primary procedure)


name: Tri-membrane wrap, per square centimeter (add-on, list separately in addition to primary procedure)


name: Matrix hd allograft dermis, per square centimeter (add-on, list separately in addition to primary procedure)


name: Shelter dm matrix, per square centimeter (add-on, list separately in addition to primary procedure)


name: Rampart dl matrix, per square centimeter (add-on, list separately in addition to primary procedure)


name: Sentry sl matrix, per square centimeter (add-on, list separately in addition to primary procedure)


name: Mantle dl matrix, per square centimeter (add-on, list separately in addition to primary procedure)


name: Palisade dm matrix, per square centimeter (add-on, list separately in addition to primary procedure)


name: Enclose tl matrix, per square centimeter (add-on, list separately in addition to primary procedure)


name: Overlay sl matrix, per square centimeter (add-on, list separately in addition to primary procedure)


name: Xceed tl matrix, per square centimeter (add-on, list separately in addition to primary procedure)


name: Penile contracture device, manual, greater than 3 lbs traction force


name: Intra-vaginal motion sensor system, provides biofeedback for pelvic floor muscle rehabilitation device


name: Electrochemiluminescent immunoassay (ECLIA) of cerebral spinal fluid for B-amyloid (Abeta42) and phospho tau (181P) (pTau181) ratio reported as positive or negative for amyloid pathology


name: Rheumatoid factor IgA and IgM, cyclic citrullinated peptide (CCP) antibodies, and scavenger receptor A (SR-A) by immunoassay, blood


name: Carbonic anhydrase VI, parotid specific/secretory protein and salivary protein 1 (SP1), IgG, IgM, and IgA antibodies, chemiluminescence, semiqualitative, blood


name: Oncology (solid tumor), DNA, qualitative, next-generation sequencing (NGS) of single-nucleotide variants (SNV) and insertion/deletions in 22 genes utilizing formalin-fixed paraffin-embedded tissue, reported as presence or absence of mutation(s), location of mutation(s), nucleotide change, and amino acid change


name: Obstetrics (preeclampsia), sFlt-1/PlGF ratio, immunoassay, utilizing serum or plasma, reported as a value


name: Oncology, spheroid cell culture, 11-drug panel (carboplatin, docetaxel, doxorubicin, etoposide, gemcitabine, niraparib, olaparib, paclitaxel, rucaparib, topotecan, veliparib) ovarian, fallopian, or peritoneal response prediction for each drug


name: Nephrology (renal transplant), quantification of CXCL10 chemokines, flow cytometry, urine, reported as pg/mL creatinine baseline and monitoring over time


name: Herpes simplex virus (HSV) types 1 and 2 and Varicella zoster virus (VZV), amplified probe technique, each pathogen reported as detected or not detected


name: Lower respiratory tract infectious agent detection, 18 bacteria, 8 viruses, and 7 antimicrobial-resistance genes, amplified probe technique, including reverse transcription for RNA targets, each analyte reported as detected or not detected with semiquantitative results for 15 bacteria


name: Hematology (venous thromboembolism [VTE]), genome-wide single-nucleotide polymorphism variants, including F2 and F5 gene analysis, and Leiden variant, by microarray analysis, saliva, report as risk score for VTE


name: Oncology (pan-solid tumor), ctDNA, utilizing plasma, next-generation sequencing (NGS) of 77 genes, 8 fusions, microsatellite instability, and tumor mutation burden, interpretative report for single-nucleotide variants, copy-number alterations, with therapy association


name: percutaneous transluminal balloon angioplasty with insertion of stent into aorta (treatment)


name: percutaneous transluminal balloon angioplasty with insertion of stent into pulmonary artery (treatment)


name: Dense calcifications in the basal ganglia seen on CT scan


name: Calcification of the small brain vessels seen on neuropathologic examination


name: Length-dependent axonal neuropathy seen on electrophysiologic studies


name: Wing-shaped conjunctival thickening in interpalpebral fissure


name: Thinning and thickening of the glomerular basement membrane


name: Hematuria (gross and microscopic) Proteinuria


name: Low carboxypeptidase-N (CPN1, 603103) levels


name: Mottled pigmentation (on axillae and groin)


name: Congenital adhesion of eyelids (may resolve spontaneously)


name: Bifurcated femur, unilateral or bilateral


name: Neutrophil bactericidal and iodination defects responsive to vitamin E (alpha-tocopherol)


name: Peripheral retinal pigmentation abnormalities


name: Decreased methionine synthase (MTR) activity


name: Left ventricular enlargement is diastole


name: Proteinaceous material and foamy macrophages seen on bronchoalveolar lavage


name: Restrictive impairment seen on pulmonary function testing


name: Patchy ground glass opacities seen on high-resolution CT


name: Hypoplastic or absent anterior pituitary


name: Abnormal sulcation of posterior cingulate cortex


name: Polymicrogyria of posterior cingulate cortex


name: Absence of the cochlear nerves, bilateral


name: Hypoplasia of cranial nerves V, VII, VIII


name: Feeding difficulties requiring gastrostomy tube feeding


name: Irregular and asymmetrically dilated lateral ventricles


name: Abnormal motor and nerve conduction velocity testing


name: Decrease in large myelinated nerve fibers seen on peroneal nerve biopsy


name: Thin myelin sheaths seen on peroneal nerve biopsy


name: Structural degeneration of myelin sheath seen on EM


name: Subtle defects in the orbicularis oris muscle (observed in carrier parents)


name: Elevated liver and muscle zinc and copper concentrations


name: Increased liver immunoreactive metallothionein


name: Mono- or multilinear dysplasia seen on bone marrow biopsy


name: Leukocyte infiltration in inflamed dermis (neutrophils, macrophages, plasma cells)


name: Elevated plasma neutrophil granule proteins


name: Elevated tumor necrosis factor-alpha (TNF, 191160)


name: Elevated serum C-reactive protein (CRP, 123260)


name: Elevated lipopolysaccharide-binding protein (LBP, 151990)


name: Elevated matrix metalloproteinase-9 (MMP9, 120361)


name: Elevated synovial fluid leukocyte counts


name: Neutrophil predominance in synovial fluid


name: Sterile abscesses and/or pathergy at vaccination sites


name: Perivascular and periadnexal polymorphic inflammatory infiltrates


name: Skin fragility with erosions/blistering after minor trauma


name: Deficit in reading, most likely related to language impairment


name: Decreased serum and plasma progranulin levels


name: Violet or brown colored hard plaque (most often on trunk, head, neck, and proximal extremities)


name: Nodular or dome-like appearance as tumor progresses


name: Dense, uniform array of spindle-shaped tumor cells with slender nuclei, intercellular collagen deposition, and small capillary blood vessels scattered throughout


name: NAXE, (GGGCC)n REPEAT EXPANSION, PROMOTER


name: No light-evoked response seen on electroretinogram (ERG)


name: Variable gingival overgrowth, mild to severe


name: Localized or generalized enlargement of gingival tissue


name: Elongated rete ridges in the squamous epithelium


name: Pseudoepitheliomatous hyperplasia of squamous epithelium with formation of papillae (in severely affected individuals)


name: Hyperkeratosis (elbows, knees, palms, sole, and MCP joints)


name: Dermal perivascular CD4+ lymphocyte-predominant infiltrate


name: Cutaneous webbing of fourth to sixth toes


name: Recurrent infections (bacterial, viral, parasitic)


name: Premature senescence of hematopoietic stem cells


name: Defective nonhomologous end-joining DNA repair


name: Maternal hypertension (after 20th week of gestation)


name: Severe cerebral amyloid angiopathy with parenchymal capillary involvement


name: Reduced responses to visual evoked potentials


name: Prominent, slightly corkscrew appearance of branches of hepatic artery seen on MRI


name: Recurrent bacterial and fungal skin infections


name: Reduced or absent corticomedullary differentiation


name: Low B cells, T cells, and NK cells, variable


name: Seizures (in 1 patient) Cerebral atrophy


name: Lipid droplets in type I fibers seen on muscle biopsy


name: Ventricular hypertrophic cardiomyopathy, mild


name: T2-weighted hyperintensity signals in the basal ganglia seen on MRI


name: Increased susceptibility to HSV infection


name: T-cell lymphopenia (mainly CD4+ T cells)


name: Increased risk for opportunistic infections


name: Cone dysfunction seen on full-field electroretinography (ERG)


name: Reduction in b-wave amplitudes seen on ERG


name: Reduced responses to light-adapted 3.0 flicker seen on ERG


name: Elevated levels of glycine in the CSF and plasma


name: Lamellation and splitting of the glomerular basement membrane


name: Markedly reduced plasma levels of NT-proANP


name: Disorganization of axonemal structures (at mid-, principal, and end pieces)


name: Disorganization of periaxonemal structures (at mid-, principal, and end pieces)


name: Abnormal, malpositioned, and/or missing peripheral microtubule doublets


name: Abnormal, malpositioned, and/or missing inner/outer dynein arms


name: Abnormal, malpositioned, and/or missing central pair


name: Abnormal, malpositioned, and/or missing outer dense fibers


name: Hypotension due to autonomic dysfunction


name: Constipation due to autonomic dysfunction


name: Decreased numbers of CD34+ hematopoietic stem cells


name: Common warts (HPV), severe, disseminated


name: Increased CD4-/CD8- DN (double negative) alpha/beta naive T cells


name: Normal or near-normal memory T cells with age


name: Peripheral sensorimotor demyelinating polyneuropathy due to post-infectious Guillain-Barre syndrome


name: Decreased activity of mitochondrial respiratory complexes (in muscle and fibroblasts)


name: Developmental regression (after illness)


name: Abnormal signal in the basal ganglia seen on MRI


name: Reticulin fibrosis on bone marrow biopsy


name: Impaired function of cobalamin-dependent enzymes MUT (609058) and MTR (156570)


name: Enlarged posterior fossa and 4th ventricle (seen on prenatal ultrasound)


name: Thin cerebellar hemispheres (in 2 fetuses)


name: Migratory myoclonic seizures seen on EEG


name: Prolonged peak time (latency) seen on visual evoked potentials


name: Absent foveal pit seen on optical coherence tomography (OCT)


name: Persistence of inner retinal layers in foveal area seen on OCT


name: Lack of outer nuclear layer widening seen on OCT


name: Lack of outer segment lengthening seen on OCT


name: Complete absence of foveal avascular zone seen on OCT angiography


name: Muscle weakness, progressive (predominantly axial and proximal)


name: Dystrophic muscle fibers seen on muscle biopsy


name: Foci of infiltrating immune cells (mostly macrophages)


name: Morphologically abnormal mitochondria seen on electron microscopy


name: Decreased complex I, II, III, and IV activity


name: Abnormal ciliary morphology and function


name: Increased parenchymal echogenicity on ultrasound


name: Type I myofiber predominance seen on muscle biopsy


name: Ultrastructural defects seen on electron microscopy


name: Reduced immunoreactivity to proteins of the dystrophin-glycoprotein complex (DGC)


name: Susceptibility to infection with pulmonary Mycobacterial tuberculosis


name: Susceptibility to infection with Listeria monocytogenes


name: No adverse response to vaccination, even BCG


name: Alveolar macrophages are deficient in ROS production


name: Impaired IgG secretion in response to stimulation


name: Neurodegeneration predominantly in supratentorial region


name: Markedly reduced insulin secretion in utero


name: Progressive loss of peripheral visual field


name: Primary loss of rod photoreceptor structure seen on optical coherence tomography (OCT)


name: Secondary loss of cone-rich central macula and fovea seen on OCT


name: Undetectable rod responses seen on electroretinography (ERG)


name: Reduced or absent cone responses seen on ERG


name: Reduced numbers of spermatocytes in testes


name: Spermatocytic arrest at zygotene-like stage seen on chromosomal spread assay


name: Reduced antimullerian hormone (AMH) levels


name: Normal response to vaccination, including BCG


name: Expansion of double-negative alpha/beta T cells


name: Increased levels of certain cytokines (IL6, IL23)


name: Protein aggregation myopathy with disproportionate diaphragmatic involvement seen on muscle biopsy


name: Abnormal globular and rod-shaped intracytoplasmic inclusions seen on muscle biopsy


name: Myofibrillar myopathy seen on muscle biopsy


name: Cox-deficient fibers seen on muscle biopsy


name: Normal or mildly increased direct bilirubin


name: Normal or mildly increased liver enzymes


name: Mild ventriculomegaly seen on brain imaging


name: Elevated brain total calcification score


name: Pyramidal or cerebellar signs, nonspecific


name: Hypoplasia of the optic nerve and chiasm


name: Temporal-parietal-occipital abnormalities seen on EEG


name: Partial arrest in first meiotic prophase


name: Uncondensed chromatin present in most spermatozoa


name: Leukodystrophy affecting the cerebral white matter


name: White matter abnormalities affecting the corticospinal tract with sparing of the cerebellum


name: Generalized spike, polyspike, polyspike-slow, and spike-slow waves seen on EEG


name: No detectable mature CD19+ memory B cells


name: Limb muscle weakness, proximal and distal


name: Myopathic and neurogenic abnormalities seen on EMG


name: Fatty degeneration of affected muscle seen on MRI


name: Complete AV canal defect (Rastelli type A)


name: Keloids (on digits at sites of minor trauma)


name: Flexion contractures (of digits due to keloid scarring)


name: Multiple broad-based fibromas (central face, neck, trunk, extremities)


name: Connective tissue with inflammatory cells (pterygium)


name: Multiple fibromas (as disease progresses)


name: Enlarged hard auricles (as disease progresses)


name: Ingrowth of vascularized connective tissue on cornea


name: Fibromas of nasal tip (as disease progresses)


name: NONSMALL CELL LUNG CANCER, RESISTANCE TO TYROSINE KINASE INHIBITOR IN, SOMATIC


name: FRONTOTEMPORAL DEMENTIA 2, SUSCEPTIBILITY TO


name: IMMUNODEFICIENCY 104, SEVERE COMBINED, SUSCEPTIBILITY TO


name: Crown, resin with predominantly base metal (procedure)


name: 16-item Transportation Security Index:-:30D:^Patient:-:TSI-16


name: How often did you spend a long time waiting because you did not have the transportation that would allow you to come and go when you wanted:Find:30D:^Patient:Ord


name: How often did you spend a long time waiting because you did not have the transportation that would allow you to come and go when you wanted


name: How often you were late getting somewhere because of a problem with transportation:Find:30D:^Patient:Ord


name: How often you were late getting somewhere because of a problem with transportation


name: How often did it take you longer to get somewhere than it would have taken you if you had different transportation:Find:30D:^Patient:Ord


name: How often did it take you longer to get somewhere than it would have taken you if you had different transportation


name: How often did you have to arrive somewhere early and wait because of the schedule of the bus, train, or person giving you a ride:Find:30D:^Patient:Ord


name: How often did you have to arrive somewhere early and wait because of the schedule of the bus, train, or person giving you a ride


name: How often did you have to reschedule an appointment because of a problem with transportation:Find:30D:^Patient:Ord


name: How often did you have to reschedule an appointment because of a problem with transportation


name: How often did you skip going somewhere because of a problem with transportation:Find:30D:^Patient:Ord


name: How often did you skip going somewhere because of a problem with transportation


name: How often were you not able to leave the house when you wanted to because of a problem with transportation:Find:30D:^Patient:Ord


name: How often were you not able to leave the house when you wanted to because of a problem with transportation


name: How often did you worry about whether or not you would be able to get somewhere because of a problem with transportation:Find:30D:^Patient:Ord


name: How often did you worry about whether or not you would be able to get somewhere because of a problem with transportation


name: How often did you feel stuck at home because of a problem with transportation:Find:30D:^Patient:Ord


name: How often did you feel stuck at home because of a problem with transportation


name: How often do you think that someone did not invite you to something because of problems with transportation:Find:30D:^Patient:Ord


name: How often do you think that someone did not invite you to something because of problems with transportation


name: How often did you feel like friends, family, or neighbors were avoiding you because you needed help with transportation:Find:30D:^Patient:Ord


name: How often did you feel like friends, family, or neighbors were avoiding you because you needed help with transportation


name: How often did you feel left out because you did not have the transportation you needed:Find:30D:^Patient:Ord


name: How often did you feel left out because you did not have the transportation you needed


name: How often did you feel bad because you did not have the transportation you needed:Find:30D:^Patient:Ord


name: How often did you feel bad because you did not have the transportation you needed


name: How often did you worry about inconveniencing your friends, family, or neighbors because you needed help with transportation:Find:30D:^Patient:Ord


name: How often did you worry about inconveniencing your friends, family, or neighbors because you needed help with transportation


name: How often did problems with transportation affect your relationships with others:Find:30D:^Patient:Ord


name: How often did problems with transportation affect your relationships with others


name: How often did you feel embarrassed because you did not have the transportation you needed:Find:30D:^Patient:Ord


name: How often did you feel embarrassed because you did not have the transportation you needed


name: Egg Comprehensive Antibody.immunoglobulin E panel


name: Guidance for aspiration of ganglion cyst:Find:Pt:XXX:Doc:US


name: Guidance for aspiration of ganglion cyst


name: Continuous glucose monitor device:TmStp:RptPeriod^start:^Patient:Qn:Reported


name: Continuous glucose monitor device:TmStp:RptPeriod^end:^Patient:Qn:Reported


name: Days continuous glucose monitor device worn:Num:RptPeriod:^Patient:Qn:Estimated


name: Days continuous glucose monitor device worn


name: Percentage of time continuous glucose monitor device worn:TimeFr:RptPeriod:^Patient:Qn:Calculated


name: Percentage of time continuous glucose monitor device worn


name: Time above range, very high:TimeFr:RptPeriod:Interstitial fluid:Qn:Calculated


name: Time above range, high:TimeFr:RptPeriod:Interstitial fluid:Qn:Calculated


name: Time below range, low:TimeFr:RptPeriod:Interstitial fluid:Qn:Calculated


name: Time below range, very low:NFr:RptPeriod:Interstitial fluid:Qn:Calculated


name: Tumor cells+Macrophages+Lymphocytes.Programmed cell death ligand 1/Viable tumor cells


name: Tumor cells.Programmed cell death ligand 1/Viable tumor cells


name: Guidance for placement of non-tunneled central venous catheter:Find:Pt:Head+Neck>Jugular vein.unilateral:Doc:US


name: Three-Item Loneliness scale:-:Pt:^Patient:-:Three-Item Loneliness Scale


name: Total score:Score:Pt:^Patient:Qn:Three-Item Loneliness Scale


name: 6-item Transportation Security Index:-:30D:^Patient:-:TSI-6


name: Botulinum neurotoxin producing species:Prid:Pt:Isolate:Nom:Endopep-MS


name: TGFBR3 & OGA gene rearrangements:Find:Pt:Tiss:Doc:FISH


name: Pediatric cancer survivorship summary:Find:Pt:^Patient:Doc


name: California encephalitis virus Ab.IgG & IgM:Imp:Pt:CSF:Ord:IF


name: Human papilloma virus 16 mRNA:PrThr:Pt:Vag:Ord:Probe.amp.tar


name: Human papilloma virus 18+45 mRNA:PrThr:Pt:Vag:Ord:Probe.amp.tar


name: Is mother of advanced age:Find:Pt:^Patient:Ord


name: t(14;19)(q32;q13) (IGH, BCL3):Find:Pt:Bld/Bone mar:Ord:FISH


name: Subepithelial autoimmune blistering disease panel:-:Pt:Ser/Plas:-


name: Subepithelial autoimmune blistering disease panel


name: Collagen type VII Ab.IgG:PrThr:Pt:Ser/Plas:Ord:IF


name: Myelin oligodendrocyte glycoprotein Ab.IgG:PrThr:Pt:Ser/Plas:Ord:IF


name: Clostridioides difficile toxin A DNA:PrThr:Pt:Stool:Ord:Probe.amp.tar


name: Clostridioides difficile toxin B DNA:PrThr:Pt:Stool:Ord:Probe.amp.tar


name: Clostridioides difficile toxin A+B DNA:PrThr:Pt:Stool:Ord:Probe.amp.tar


name: Escherichia coli shiga-like toxin DNA:PrThr:Pt:Stool:Ord:Probe.amp.tar


name: Herpes simplex virus 1 DNA:PrThr:Pt:Thrt:Ord:Probe.amp.tar


name: Herpes simplex virus 2 DNA:PrThr:Pt:Thrt:Ord:Probe.amp.tar


name: Ureaplasma urealyticum+Ureaplasma parvum DNA:PrThr:Pt:Thrt:Ord:Probe.amp.tar


name: Ureaplasma urealyticum+Ureaplasma parvum DNA:PrThr:Pt:Vag:Ord:Probe.amp.tar


name: Ureaplasma urealyticum+Ureaplasma parvum DNA:PrThr:Pt:Urine:Ord:Probe.amp.tar


name: Herpes simplex virus 2 DNA:PrThr:Pt:Anal:Ord:Probe.amp.tar


name: Ureaplasma urealyticum+Ureaplasma parvum DNA:PrThr:Pt:Anal:Ord:Probe.amp.tar


name: Monkeypox virus clade Ia DNA:PrThr:Pt:Specimen:Ord:Probe.amp.tar


name: Monkeypox virus clade Ib DNA:PrThr:Pt:Specimen:Ord:Probe.amp.tar


name: Bacteroides fragilis DNA:PrThr:Pt:Body fld:Ord:Non-probe.amp.tar


name: Candida albicans DNA:PrThr:Pt:Body fld:Ord:Non-probe.amp.tar


name: Candida auris DNA:PrThr:Pt:Body fld:Ord:Non-probe.amp.tar


name: Candida glabrata DNA:PrThr:Pt:Body fld:Ord:Non-probe.amp.tar


name: Candida krusei DNA:PrThr:Pt:Body fld:Ord:Non-probe.amp.tar


name: Candida parapsilosis DNA:PrThr:Pt:Body fld:Ord:Non-probe.amp.tar


name: Candida tropicalis DNA:PrThr:Pt:Body fld:Ord:Non-probe.amp.tar


name: Escherichia coli DNA:PrThr:Pt:Body fld:Ord:Non-probe.amp.tar


name: Klebsiella aerogenes DNA:PrThr:Pt:Body fld:Ord:Non-probe.amp.tar


name: Cryptococcus gattii+neoformans DNA:PrThr:Pt:Body fld:Ord:Non-probe.amp.tar


name: Enterobacter cloacae complex DNA:PrThr:Pt:Body fld:Ord:Non-probe.amp.tar


name: Enterococcus faecium DNA:PrThr:Pt:Body fld:Ord:Non-probe.amp.tar


name: Enterococcus faecalis DNA:PrThr:Pt:Body fld:Ord:Non-probe.amp.tar


name: Streptococcus agalactiae DNA:PrThr:Pt:Body fld:Ord:Non-probe.amp.tar


name: Haemophilus influenzae DNA:PrThr:Pt:Body fld:Ord:Non-probe.amp.tar


name: Klebsiella oxytoca DNA:PrThr:Pt:Body fld:Ord:Non-probe.amp.tar


name: Klebsiella pneumoniae DNA:PrThr:Pt:Body fld:Ord:Non-probe.amp.tar


name: Listeria monocytogenes DNA:PrThr:Pt:Body fld:Ord:Non-probe.amp.tar


name: Neisseria meningitidis DNA:PrThr:Pt:Body fld:Ord:Non-probe.amp.tar


name: Proteus sp DNA:PrThr:Pt:Body fld:Ord:Non-probe.amp.tar


name: Pseudomonas aeruginosa DNA:PrThr:Pt:Body fld:Ord:Non-probe.amp.tar


name: Staphylococcus epidermidis DNA:PrThr:Pt:Body fld:Ord:Non-probe.amp.tar


name: Serratia marcescens DNA:PrThr:Pt:Body fld:Ord:Non-probe.amp.tar


name: Staphylococcus aureus DNA:PrThr:Pt:Body fld:Ord:Non-probe.amp.tar